Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients

November 10, 2026 updated by: Linda Zhong, Nanyang Technological University

Investigating the Efficacy and Safety of Electroacupuncture in the Treatment of Esophageal Symptoms in Non-erosive Reflux Disease (NERD) Patients: A Pilot, Randomized Double-blinded, Sham-controlled Trial

The goal of this clinical trial is to learn if acupuncture works to treat non-erosive reflux disease (NERD) patients. The main questions it aims to answer are:

  1. Electroacupuncture (EA) is superior to sham EA in terms of easing the symptom severity of NERD.
  2. Acupuncture is able to influence gastrointestinal function, autonomic regulation, and stress responses in NERD patients.

Participants will:

  1. Receive acupuncture treatment twice per week for 6 weeks.
  2. Leave plasma, serum, saliva, stool, and urine samples at baseline, mid-treatment, and end-of-treatment.
  3. Complete patient-reported-outcomes (PROs) at baseline, mid-treatment, and end-of-treatment

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

96

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 21 to 75 years at the time of consent;
  • Presence of heartburn, regurgitation or chest pain before screening with a frequency of at least twice a week;
  • No evidence of esophageal mucosal injury on endoscopy within the past 5 years;
  • GERD-Q score ≥8 (indicating active GERD symptoms);
  • Ability and willingness to provide written informed consent to participate.

Exclusion Criteria:

  • Structural or organic gastrointestinal disease, including but not limited to:

    1. gastrointestinal malignancy,
    2. eosinophilic esophagitis,
    3. esophageal stricture, varices, or infections,
    4. active peptic ulcer disease,
    5. gastric or duodenal tumors;
  • Presence of alarming symptoms (e.g. severe dysphagia, hematemesis, unexplained weight loss, or hematochezia, etc.);

  • History of digestive tract surgery or esophageal interventions, including chemotherapy, radiotherapy, radiofrequency ablation, endoscopic mucosal resection, or cryotherapy;

  • Use of prohibited medical treatment:

    1. acupuncture treatment on the abdomen and chest within past 1 month,
    2. concomitant medication affecting gastrointestinal motility or visceral sensitivity (antidiarrheals, antidepressants, narcotic analgesics, anticholinergics, etc.),
    3. antibiotics, prebiotics, probiotics, or immunosuppressants within 1 month prior to screening;
  • Presence of an implanted cardiac pacemaker;

  • History of hypersensitivity to acupuncture, or needle phobia;

  • Severe psychiatric illness (e.g. schizophrenia, major depression, dementia), cognitive impairment, or other conditions likely to compromise adherence to study procedures;

  • Pregnant or breastfeeding;

  • Current participation in other clinical trials that could interfere with study outcomes.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Electroacupuncture (EA)

The WHO Standardized Acupuncture Points Location will be used to identify the location of these acupoints: ST36 Zusanli, PC6 Neiguan, CV12 Zhongwan, LR3 Taichong, SP4 Gongsun; and auxiliary acupoints added according to symptom severity: PC7 Daling, ST44 Neiting, EX-HN3 Yintang, ST37 Shangjuxu, SP6 Sanyinjiao, LU7 Lieque. After sterilizing the skin, needles of 0.25 mm in diameter and 25-40 mm in length will be inserted into the acupoints to a depth of 10-30 mm outward and upward slightly. Needles will be lifted, thrust, and twirled evenly 3 times to achieve "de-qi". Paired electrodes of the EA apparatus will be attached transversely to the acupoint respectively with a continuous wave of 2/100 Hz and a current intensity of 1-5 mA (preferably with the skin around the acupoints shivering mildly without pain) for 30 min.

The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.

Sham Comparator: Sham-electroacupuncture (SEA)

The sham electroacupuncture group (SEA) penetrates acupuncture on non-acupuncture points (1 B-cun away from the acupuncture point and meridian). The same type of acupuncture needles will be used for SEA with the exact skin sterilization method. Insertion depth will be approximately less than 10 mm. The electrostimulator will not be switched on for these patients. All needles will be removed after 30 min of needle retention.

The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gastroesophageal Reflux Disease Questionnaire (GERDQ)
Time Frame: From enrollment to the end of follow-up at 16 weeks

≥ 50% reduction in total GERD-Q score or normalization (<8)

From enrollment to the end of follow-up at 16 weeks
Gastrointestinal Symptom Rating scale (GSRS)
Time Frame: From enrollment to the end of follow-up at 16 weeks

≥ 0.5 point decrease in mean GSRS Reflux domain value

From enrollment to the end of follow-up at 16 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD)
Time Frame: From enrollment to the end of follow-up at 16 weeks

≥ 0.5 point improvement on the mean QOLRAD score

From enrollment to the end of follow-up at 16 weeks
Euro QoL (EQ-5D-5L)
Time Frame: From enrollment to the end of follow-up at 16 weeks

change in index utility

From enrollment to the end of follow-up at 16 weeks
Hospital Anxiety and Depression Scale (HADS)
Time Frame: From enrollment to the end of follow-up at 16 weeks

categorical shift from ≥ 11 to < 11 or ≥ 8 to < 8, or ≥ 1.5 point reduction per HADS-A and HADS-D subscale

From enrollment to the end of follow-up at 16 weeks
Visceral Sensitivity Index (VSI)
Time Frame: From enrollment to the end of follow-up at 16 weeks

≥ 15% reduction from baseline

From enrollment to the end of follow-up at 16 weeks
Esophageal Hypervigilance and Anxiety Scale (EHAS) Short Form
Time Frame: From enrollment to the end of follow-up at 16 weeks

≥ 15% reduction from baseline

From enrollment to the end of follow-up at 16 weeks
Simplified Constitution of Chinese Medicine Questionnaire (CCMQ)
Time Frame: At baseline
At baseline
Traditional Chinese medicine functional gastrointestinal disorders syndrome scale (TCM-FGID)
Time Frame: From enrollment to the end of follow-up at 16 weeks

(Total syndrome score before treatment - Total syndrome score after treatment) / Total syndrome score before treatment × 100%

From enrollment to the end of follow-up at 16 weeks
Bang's blinding index (BBI)
Time Frame: End of first week and sixth week of intervention
End of first week and sixth week of intervention
James' blinding index (JBI)
Time Frame: End of first week and sixth week of intervention
End of first week and sixth week of intervention
Patient's global impression of change (PGIC)
Time Frame: From mid-treatment to the end of follow-up at 16 week
From mid-treatment to the end of follow-up at 16 week
Daily patient diary
Time Frame: From enrollment to the end of follow-up at 16 weeks
From enrollment to the end of follow-up at 16 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Linda LD Zhong, PhD, Nanyang Technological University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

March 1, 2028

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD sharing will be available upon request.

IPD Sharing Time Frame

Data will become available within 7 years after completion of the clinical trial.

IPD Sharing Access Criteria

Individual participant data (IPD) will be made available to qualified researchers upon request. To access the data, researchers must submit a formal request, which will be reviewed and approved by the data-sharing committee. Data access will be granted for research purposes only and will require adherence to data use agreements and ethics guidelines.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe